Analysts expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating) to report sales of $3.33 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for Arcturus Therapeutics’ earnings, with the highest sales estimate coming in at $6.29 million and the lowest estimate coming in at $1.32 million. Arcturus Therapeutics reported […]
Equities research analysts expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating) to post $3.33 million in sales for the current quarter, Zacks reports. Four analysts have issued estimates for Arcturus Therapeutics’ earnings, with the lowest sales estimate coming in at $1.32 million and the highest estimate coming in at $6.29 million. Arcturus Therapeutics reported […]
Equities research analysts predict that Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating) will post earnings of ($1.29) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Arcturus Therapeutics’ earnings. The highest EPS estimate is ($1.02) and the lowest is ($1.76). Arcturus Therapeutics reported earnings per share […]
Arcturus Therapeutics (NASDAQ:ARCT – Get Rating) was downgraded by equities researchers at Citigroup from a “buy” rating to a “neutral” rating in a research report issued on Thursday, Briefing.com reports. They currently have a $29.00 price target on the biotechnology company’s stock, down from their previous price target of $86.00. Citigroup’s price target would suggest […]
Brokerages expect Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT – Get Rating) to report earnings of ($1.29) per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Arcturus Therapeutics’ earnings, with estimates ranging from ($1.76) to ($1.02). Arcturus Therapeutics reported earnings per share of ($2.15) during the same quarter last […]